Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).
Yi-Xiu LongYue SunRui-Zhi LiuMing-Yi ZhangJing ZhaoYu-Qing WangYu-Wen ZhouKe ChengYe ChenCai-Rong ZhuZhenhua LiuPublished in: Current oncology (Toronto, Ont.) (2022)
In comparison to PD-1/L1 inhibitor treatment alone, combining chemotherapy with PD-1/L1 inhibitors might reduce the risk of IRP in the general population. Furthermore, PD-1 inhibitors in combination with chemotherapy were correlated with a decreased risk of IRP compared to PD-1 inhibitor treatment alone. In contrast to the I group, the I+C group exhibited a lower risk of IRP, especially for NSCLC patients.
Keyphrases
- systematic review
- locally advanced
- small cell lung cancer
- newly diagnosed
- squamous cell carcinoma
- meta analyses
- radiation therapy
- randomized controlled trial
- computed tomography
- rheumatoid arthritis
- chronic kidney disease
- combination therapy
- rectal cancer
- interstitial lung disease
- patient reported outcomes
- replacement therapy
- idiopathic pulmonary fibrosis
- smoking cessation
- peritoneal dialysis